Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Tomofumi Moriyama"'
Autor:
Yuka Kurokawa, Yusuke Kaida, Takuma Hazama, Yosuke Nakayama, Takaomi Otome, Ryo Shibata, Sakuya Ito, Goh Kodama, Nao Nakamura, Takatoshi Kambe, Tomofumi Moriyama, Akiko Nagata, Aki Minami, Ryotaro Ando, Yoshifumi Wada, Miki Sugiyama, Michiaki Usui, Michio Chiba, Atsuo Moriyama, Atsuko Ohara, Hiroshi Miyazaki, Tatsuyuki Kakuma, Kei Fukami
Publikováno v:
Renal Replacement Therapy, Vol 6, Iss 1, Pp 1-10 (2020)
Abstract Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalc
Externí odkaz:
https://doaj.org/article/44fc4637fec249aab21820b2c2f391c2
Publikováno v:
Internal Medicine; 2023, Vol. 62 Issue 21, p3203-3207, 5p
Autor:
Tomofumi Moriyama, Kei Fukami
Publikováno v:
Circulation Journal. 85:1719-1721
Autor:
Aki Minami, Takuma Hazama, Tatsuyuki Kakuma, Akiko Nagata, Kei Fukami, Ryo Shibata, Miki Sugiyama, Yoshifumi Wada, Nao Nakamura, Yusuke Kaida, Ryotaro Ando, Michio Chiba, Sakuya Ito, Atsuko Ohara, Atsuo Moriyama, Michiaki Usui, Yosuke Nakayama, Tomofumi Moriyama, Goh Kodama, Takaomi Otome, Yuka Kurokawa, Hiroshi Miyazaki, Takatoshi Kambe
Publikováno v:
Renal Replacement Therapy, Vol 6, Iss 1, Pp 1-10 (2020)
Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalcetide in
Autor:
Sakuya Ito, Kensei Taguchi, Yusuke Kaida, Goh Kodama, Tomofumi Moriyama, Yunosuke Yokota, Masami Shinohara, Kyoko Tashiro, Kei Fukami
Publikováno v:
Journal of Hypertension. 41:e374
Autor:
Akinari Sekine, Sumi Hidaka, Tomofumi Moriyama, Yasuto Shikida, Keiji Shimazu, Eiji Ishikawa, Kiyotaka Uchiyama, Hiroshi Kataoka, Haruna Kawano, Mahiro Kurashige, Mai Sato, Tatsuya Suwabe, Shinya Nakatani, Tadashi Otsuka, Hirayasu Kai, Kan Katayama, Shiho Makabe, Shun Manabe, Wataru Shimabukuro, Koichi Nakanishi, Saori Nishio, Fumihiko Hattanda, Kazushige Hanaoka, Kenichiro Miura, Hiroki Hayashi, Junichi Hoshino, Ken Tsuchiya, Toshio Mochizuki, Shigeo Horie, Ichiei Narita, Satoru Muto
Publikováno v:
Journal of Clinical Medicine. 11:6528
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cystic kidney disease, with patients often having a positive family history that is characterized by a similar phenotype. However, in atypical cases, particularly thos
Autor:
Takuma Hazama, Kiyomi Koike, Ryo Shibata, Sakuya Ito, Yusuke Kaida, Nao Nakamura, Tomofumi Moriyama, Hirotane Chiba, Daisuke Wakasugi, Kei Fukami, Seiya Okuda, Yuka Kurokawa, Tetsurou Imai, Kengo Urae
Publikováno v:
CEN Case Reports. 8:205-211
A 65-year-old male patient with nephrotic syndrome was admitted to our hospital due to worsening systemic edema and purpura on the limbs. He had an impaired renal function, low serum complement level, and elevated rheumatoid factor level. He was posi
Autor:
Nao Nakamura, Mikiko Soejima, Takuma Hazama, Utako Ueda, Yosuke Nakayama, Ryo Shibata, Tomofumi Moriyama, Yoshiro Koda, Yuka Kurokawa, Kanji Ota, Yoshimi Takamiya, Yunosuke Yokota, Yusuke Kaida, Kei Fukami, Sakuya Ito, Junko Yano, Goh Kodama
Publikováno v:
Clinical and Experimental Nephrology
BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder caused by mutations in the polycystic kidney disease (PKD) gene. Although tolvaptan has benefits for renal involvement, the different effects depending on the gen
Autor:
Kurokawa, Yuka, Kaida, Yusuke, Hazama, Takuma, Nakayama, Yosuke, Takaomi Otome, Shibata, Ryo, Sakuya Ito, Kodama, Goh, Nakamura, Nao, Kambe, Takatoshi, Tomofumi Moriyama, Nagata, Akiko, Minami, Aki, Ando, Ryotaro, Wada, Yoshifumi, Sugiyama, Miki, Usui, Michiaki, Chiba, Michio, Moriyama, Atsuo, Ohara, Atsuko, Miyazaki, Hiroshi, Kakuma, Tatsuyuki, Fukami, Kei
Additional file 1: Supplementary Table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ad68e3a4769b6e344d6b29f83029ee4
Autor:
Kaoru Ueda, Kensei Taguchi, Goh Kodama, Miki Sugiyama, Tomohisa Minezaki, Junko Yano, Yusuke Kaida, Chika Yoshida, Nao Nakamura, Akiko Nagata, Yuka Kurokawa, Sho-ichi Yamagishi, Yosuke Nakayama, Tomofumi Moriyama, Kazutaka Shibatomi, Kei Fukami, Sakuya Ito
Publikováno v:
Clinical and Experimental Nephrology. 22:35-44
Hyperkalemia is prevalent in end-stage renal disease patients, being involved in life-threatening arrhythmias. Although polystyrene sulfonate (PS) is commonly used for the treatment of hyperkalemia, direct comparison of effects between calcium and so